231 related articles for article (PubMed ID: 21718136)
21. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
[TBL] [Abstract][Full Text] [Related]
22. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
23. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.
Cortelezzi A; Gritti G; Laurenti L; Cuneo A; Ciolli S; Di Renzo N; Musto P; Mauro FR; Cascavilla N; Falchi L; Zallio F; Callea V; Maura F; Martinelli S; Piciocchi A; Reda G; Foà R;
Br J Haematol; 2012 Feb; 156(4):481-9. PubMed ID: 22150204
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Br J Haematol; 2009 Jan; 144(1):78-85. PubMed ID: 19016731
[TBL] [Abstract][Full Text] [Related]
25. High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.
Majolino I; Ladetto M; Locasciulli A; Drandi D; Benedetti F; Gallamini A; Chisesi T; De Blasio A; Boccadoro M; Tarella C
Med Oncol; 2006; 23(3):359-68. PubMed ID: 17018893
[TBL] [Abstract][Full Text] [Related]
26. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
27. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
[TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.
Eketorp Sylvan S; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Ann Hematol; 2014 Oct; 93(10):1725-33. PubMed ID: 24844780
[TBL] [Abstract][Full Text] [Related]
30. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P
J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413
[TBL] [Abstract][Full Text] [Related]
32. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A
Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923
[TBL] [Abstract][Full Text] [Related]
33. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
Wierda WG; Padmanabhan S; Chan GW; Gupta IV; Lisby S; Osterborg A;
Blood; 2011 Nov; 118(19):5126-9. PubMed ID: 21856867
[TBL] [Abstract][Full Text] [Related]
34. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
[TBL] [Abstract][Full Text] [Related]
35. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
Tam CS; O'Brien S; Lerner S; Khouri I; Ferrajoli A; Faderl S; Browning M; Tsimberidou AM; Kantarjian H; Wierda WG
Leuk Lymphoma; 2007 Oct; 48(10):1931-9. PubMed ID: 17917961
[TBL] [Abstract][Full Text] [Related]
36. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
[TBL] [Abstract][Full Text] [Related]
37. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
38. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine in chronic lymphocytic leukaemia.
Elter T; Hallek M; Engert A
Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
Blood; 2002 Aug; 100(3):768-73. PubMed ID: 12130484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
